<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00272064</url>
  </required_header>
  <id_info>
    <org_study_id>HMR1964A_3514</org_study_id>
    <secondary_id>EudraCT # : 2004-002731-62</secondary_id>
    <nct_id>NCT00272064</nct_id>
  </id_info>
  <brief_title>ELEONOR STUDY: Insulin Glulisine in Type 2 Diabetes Mellitus.</brief_title>
  <official_title>Optimisation of Insulin Treatment of Type 2 Diabetes Mellitus by Telecare Assistance for Self Monitoring of Blood Glucose (SMBG).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      -  The primary objective of the present study is to verify the superiority of Telecare&#xD;
           program vs. standard SMBG program in terms of mean HbA1c value (- 0,5%) at end-point.&#xD;
&#xD;
        -  The secondary objectives of the study are the assessment of: total daily dose of&#xD;
           insulin, changes in glycaemic and lipid profile, frequency of hypoglycaemias, changes in&#xD;
           weight, health-related quality of life, cost-effectiveness of Telecare program vs.&#xD;
           common ambulatory program; general safety (adverse event profile, other routine&#xD;
           laboratory parameters).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes of glycosilated haemoglobin (HbA1c)</measure>
    <time_frame>At least 12 weeks from baseline (visit 3)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in fasting plasma glucose</measure>
    <time_frame>At each visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in plasma insulin levels</measure>
    <time_frame>At each visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Self-monitoring of Blood Glucose (SMBG)</measure>
    <time_frame>for the total study duration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Amplitude Glucose Excursion (MAGE)</measure>
    <time_frame>for the total study duration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in lipid profile</measure>
    <time_frame>V1 (screening) and V5 (end of treatment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body weight - Body Mass Index</measure>
    <time_frame>V1 (screening), V3 (start of titration), V4 (after 12 weeks of treatment), V5 (end of treatment), V6 (end of follow-up)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total daily dose of insulins (glargine and glulisine)</measure>
    <time_frame>At each visit (starting from V2 for glargine and from V3 for glulisine)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health related Quality of Life</measure>
    <time_frame>V2 (start of titration), V4 (after 12 weeks of treatment), V5 (end of treatment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypoglycemic episodes</measure>
    <time_frame>for the total study duration</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">352</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Telecare system</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Self Monitoring Blood Glucose (SMBG)system.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin glulisine</intervention_name>
    <description>individualized, once daily, dose aiming at 2h post-prandial plasma glucose goal &lt; 140 mg/dl (7.8 mmol/l) in the optimized treatment phase, since visit 3, subcutaneous</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin glargine</intervention_name>
    <description>individualized, once daily, dose to reach mean fasting plasma glucose (FPG) &lt;= 126 mg/dl (7.0 mmol/l), since randomization, subcutaneous</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>1000 mg b.i.d, since the qualification phase, oral</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Diagnosis of type 2 Diabetes Mellitus&#xD;
&#xD;
          -  Patients treated with combined oral antidiabetic drugs(as fixed combination or&#xD;
             simultaneous administration) or with metformin in monotherapy at maximal doses for at&#xD;
             least 3 months&#xD;
&#xD;
          -  Patients having BMI &gt; 25 Kg/m2;&#xD;
&#xD;
          -  Patients having a HbA1c ≥ 7.5 % and ≤ 11 %&#xD;
&#xD;
          -  Female patients must be menopausal, surgically sterile, or using effective&#xD;
             contraceptive measures;&#xD;
&#xD;
          -  Female of childbearing potential must use effective contraceptive measures for at&#xD;
             least 1 month prior to the entry into the study and should continue to use the same&#xD;
             contraceptive method during the overall study period.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Patients diagnosed with type 1 insulin dependent Diabetes Mellitus;&#xD;
&#xD;
          -  History of two or more severe hypoglycaemic episodes within the past 3 months or&#xD;
             history of unawareness hypoglycaemia;&#xD;
&#xD;
          -  Active proliferative diabetic retinopathy, as defined by the application of focal or&#xD;
             panretinal photocoagulation or vitrectomy, in the 6 months prior to visit 1, or any&#xD;
             other unstable (rapidly progressing) retinopathy that may require surgical treatment&#xD;
             (including laser photocoagulation);&#xD;
&#xD;
          -  Impaired renal function&#xD;
&#xD;
          -  Impaired liver function&#xD;
&#xD;
          -  History of hypersensitivity to insulin or insulin analogues or any of the excipients&#xD;
             in the Insulin glulisine and Insulin glargine formulation&#xD;
&#xD;
          -  History of hypersensitivity to metformin;&#xD;
&#xD;
          -  Pregnant or breast-feeding women, or women planning to become pregnant during the&#xD;
             study;&#xD;
&#xD;
          -  Failure to use adequate contraception (women of current reproductive potential only);&#xD;
&#xD;
          -  Any clinically significant major organ system disease such as relevant cardiovascular,&#xD;
             gastrointestinal, hepatic, neurological, endocrine, haematological or other major&#xD;
             systemic diseases or infective diseases;&#xD;
&#xD;
          -  History of drug or alcohol abuse within the last 2 years or current addiction to&#xD;
             substances of abuse;&#xD;
&#xD;
          -  Night shift workers;&#xD;
&#xD;
          -  Receipt of an experimental drug or use of an experimental device within the 30 days&#xD;
             prior to study entry;&#xD;
&#xD;
          -  Mental condition rendering the subject unable to understand the nature, scope, and&#xD;
             possible consequences of the study;&#xD;
&#xD;
          -  Treatment or likelihood of requiring treatment during the study period with drugs not&#xD;
             permitted by the clinical study protocol;&#xD;
&#xD;
          -  Any disease or condition including abuse of illicit drugs, prescription medicines or&#xD;
             alcohol that in the opinion of the investigator or sponsor may interfere with the&#xD;
             completion of the study;&#xD;
&#xD;
          -  Subject unlikely to comply with protocol, e.g., uncooperative attitude, inability to&#xD;
             return for follow-up visits, and unlikelihood of completing the study procedures;&#xD;
&#xD;
          -  Subject is the investigator or any sub investigator, research assistant, pharmacist,&#xD;
             study coordinator, other staff or relative thereof directly involved in the conduct of&#xD;
             the protocol;&#xD;
&#xD;
          -  Previous enrolment in the present study.&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>PAIZIS GEORGES, MD</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>December 2009</verification_date>
  <study_first_submitted>January 2, 2006</study_first_submitted>
  <study_first_submitted_qc>January 2, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 4, 2006</study_first_posted>
  <last_update_submitted>December 4, 2009</last_update_submitted>
  <last_update_submitted_qc>December 4, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 7, 2009</last_update_posted>
  <responsible_party>
    <name_title>Medical Affairs Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
    <mesh_term>Insulin glulisine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

